Introduction
Cardiovascular disease is the main cause of death in patients with type 2 diabetes (T2D). Almost 80% of such patients are believed to die from cardiovascular diseases such as myocardial infarction or stroke. Primary coronary intervention with stent implantation is now widely performed for patients with symptomatic coronary artery diseases. Although the development of drug-eluting stents has reduced the incidence of restenosis after coronary intervention, restenosis of the intervened vessel is still a critical issue of significant magnitude. It is now known that glucagon like peptide-1 (GLP-1) treatment improves cardiac function in cases of heart failure or after acute myocardial infarction. In a rat model of chronic heart failure, 11 weeks of treatment with GLP-1 improved the left ventricular (LV) ejection fraction and end diastolic pressure. 2 Activation of the GLP-1 receptor with GLP-1 significantly mitigated myocardial injury in a study using isolated perfused rat hearts. 3 Furthermore, in dogs with dilated cardiomyopathy induced by excessive pacing, the stimulation of GLP signalling with GLP-1 improved their cardiac performance. 4 In human patients with acute myocardial ischemia, a GLP-1 infusion improved regional and global cardiac functions. 5 In a recent large clinical trial, the rate of the first occurrence of death from cardiovascular causes, non-fatal myocardial infarction, or non-fatal stroke among patients with T2D was lower with liraglutide than with placebo. 6 In this context, it would be interesting to investigate whether activation of the GLP-1 receptor has a role in preventing restenosis after vascular injury, and more generally has potential antiatherosclerotic properties.
We have shown that the continuous expression of GLP-1 in vivo regenerates pancreatic b-cells and improves glucose homeostasis in mice, using an adenoviral vector containing the cytomegalovirus promoter/enhancer and albumin leader sequence followed by the GLP-1 cDNA sequence (rAd-GLP-1). 7 Here, we investigated the effect of direct rAd-
GLP-1 delivery to injured vessels, and systemic injection of exenatide, a GLP-1 agonist, in reducing the occurrence of restenosis after a vascular balloon injury in an animal model of insulin resistance. Among many factors, the expression and activity of matrix metalloproteinases (MMPs) have been reported to correlate with the macrovascular complications of diabetes. 8, 9 Nuclear factor-kappa-B (NF-jB), a core mediator in the inflammatory cascade, is activated in the milieu of atherosclerosis and insulin resistance. Therefore, we investigated alterations in MMPs and NF-jB levels after treatment using injured vessels obtained from the study animals, and in vascular cell lines to elucidate possible related mechanisms.
Methods

Construction of a recombinant adenovirus expressing GLP-1 (rAd-GLP-1)
We constructed a recombinant adenoviral vector containing the CMV promoter/enhancer and albumin leader sequence (25 amino acids) followed by the GLP-1 cDNA sequence (amino acids 7-37), which encodes active GLP-1 (rAd-GLP-1). As a control, we replaced the albumin leader-GLP-1 cDNA with the b-galactosidase cDNA in the same vector (rAd-bGAL). The expression of GLP-1 by the rAd-GLP-1 vector was confirmed by reverse transcriptase-polymerase chain reaction (RT-PCR) using an immortalized human hepatocyte line. 10 Briefly, expression of GLP-1 mRNA was first detected at 8 h after rAd-GLP-1 infection and increased further by 24 h, whereas GLP-1 mRNA was not detected in rAd-bGAL-infected cells. 7 
Study animals and care
Thirty-six Otsuka Long-Evans Tokushima Fatty (OLETF) rats (4 weeks old, male), the animal model for obese T2D, were donated by Japanese Otsuka Pharmaceuticals (Otsuka Holdings Co., Ltd., Tokyo, Japan). OLETF rats naturally develop T2D around 24 weeks of age and have been used in studies investigating glucose metabolism and cardiovascular complications in this condition. 11 After being raised in plastic cages in an air-conditioned room at 22 ± 2 C and 55 ± 10% humidity for 24 weeks, 28 week-old rats weighing 500-600 g were studied. The animals were all allowed free access to water and regular chow diet (Purina Korea, Seoul, South Korea), and diet and water consumption were recorded once a week. Animals were weighed twice a week at the same time in the morning. Rats were placed into three groups: (1) normal saline subcutaneous (SC) injection þ rAd-bGAL delivery (NS þ rAd-bGAL) as a control, (2) exenatide SC injection þ rAd-bGAL delivery (Exenatide þ rAd-bGAL), and (3) normal saline (NS) SC injection þ rAd-GLP-1 delivery (NS þ rAd-GLP-1) (n ¼ 12 per group). Exenatide (0.5 lg/kg) or normal saline was administered twice from 1 week before to 2 weeks after carotid injury.
Animal experiments were performed in compliance with the Guide for Experimental Animal Research of the Laboratory for Experimental Animal Research, Clinical Research Institute, Seoul National University Bundang Hospital, Republic of Korea. All animal procedures were performed to conform with the National Institutes of Health guidelines.
Animal studies
Rat carotid artery balloon denudation injury
A previously well-established rat carotid artery balloon injury model was used in this study. 12 Rats were anesthetized with a combination of anaesthetics (ketamine, 70 mg/kg; xylazine, 7 mg/kg IP; Yuhan Corp, Seoul, South Korea). After the left external carotid artery was exposed, heparin (30 IU) was administered systemically via the external jugular vein. A 2F Fogarty embolectomy catheter (Baxter Healthcare Corp, IL, USA) was introduced into an external carotid arteriotomy incision, advanced to the common carotid artery, and inflated with 0.2-0.25 mL of normal saline and withdrawn 10 times with rotation. After clamping both the common carotid and the internal carotid arteries proximally, mixtures containing 5 Â 10 8 pfu of adenovirus containing either rAd-GLP-1 or rAd-bGAL diluted to a total volume of 100 lL were instilled via the arterial segment between the two clamps. 13 Clamping of the artery was released at 20 min after instillation.
Morphometric analysis
Two weeks after balloon injury, rats were euthanized with a lethal dose of pentobarbital (150 mg/kg), and carotid arteries were fixed by perfusion at 120 mmHg with 4% formaldehyde via an 18G intravenous cannula placed retrograde in the abdominal aorta. Tissues were then embedded in paraffin, and sections were stained with H&E. The extent of neointimal formation in histologically stained sections was quantified by computed planimetry. The cross-sectional areas of the blood vessel layers, i.e. the lumen, intimal, and medial areas, are quantified in 3 different sections (proximal, middle, and distal) using an Image-ProV R Plus Analyser Version 4.5 (Media Cybernetics, Silver Spring, MD, USA). The intima-media ratio (IMR) was calculated from the mean of these determinations.
Immunoblot analysis of GLP-1 receptors in carotid arteries
Harvested vessel tissues were homogenized with cell lysis buffer (Cell Signalling, Danvers, MA, USA) containing 20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM Na 2 EDTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate, 1 mM Na 3 VO 4 , 1 mg/ml leupeptin, and 1 mM phenylmethylsulfonyl fluoride for 30 min at 4 C, and protein lysate concentrations were measured using Bradford protein assay kits (BioRad, Hercules, CA, USA). The same amounts of proteins from whole cell lysates were subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred onto methanol-treated polyvinylidene difluoride membranes (Millipore Co., Bedford, MA, USA). After blocking the membrane with Tris-buffered saline with Tween 20 (TBS-T) containing 5% blocking buffer for 1 h at room temperature, they were washed with TBS-T and incubated with primary antibodies against GLP-1 receptor (Santa Cruz Biochemicals, Dallas, TX, USA) or c-tubulin (Sigma Aldrich, St Louis, MO, USA) for 1 h at room temperature or overnight at 4 C. The membranes were washed three times with TBS-T for 10 min and then incubated for 1 h at room temperature with horseradish peroxidase-conjugated secondary antibodies. After washing, the bands were detected using enhanced chemiluminescence reagents (Santa Cruz Biochemicals).
Immunohistochemical staining for proliferation and apoptosis
To determine whether exenatide injection or rAd-GLP-1 delivery could affect cell proliferation directly, we measured cell proliferation by immunostaining for proliferating cell nuclear antigen (PCNA) in the tissue sections of injured arteries. Briefly, deparaffinized specimens were treated with protease K for 4 min, and endogenous peroxidase was then quenched with a methanol/peroxidase solution. 
Immunohistochemical staining of CD68 for monocytes and CD31 for endothelial cells
For immunohistochemistry of CD68 and CD31, sections were rehydrated, blocked with 5% goat serum and 0.01% Triton X-100 in PBS, and incubated with the monocyte/macrophage marker anti-CD68 (Abcam, Cambridge, MA, USA) or the endothelial cell marker anti-CD31 (AbD Serotec, Kidlington, UK) for 1 h. After they had been rinsed with PBS, horseradish peroxidase-conjugated antibody to rabbit IgG or mouse IgG was applied for 20 min. Sections were exposed for 4 min to 0.04% diaminobenzidine tetrahydrochloride (DAB) in 0.05 mol/L Tris-maleate buffer (pH 7.6) with 0.006% H 2 O 2 and counterstained with hematoxylin.
Biochemical markers associated with cardiovascular risk
An intraperitoneal glucose tolerance test (IPGTT) was performed at baseline and 3 weeks after exenatide or normal saline injections. After the 10 h fasting glucose concentration had been measured, each animal was injected intraperitoneally with 1.5 g/kg of a 1 mol/L glucose solution.
Blood samples (about 10 lL) were collected from the tail at 30, 60, and 120 min after the glucose load. Plasma glucose concentration was measured using reagent strips read in a glucose meter (YSI 2300-STAT, Yellow Springs, OH, USA). The homeostasis model assessment of the insulin resistance (HOMA-IR) and pancreatic b-cell function (HOMA-b) were calculated using fasting insulin and glucose concentrations. 15 In addition, the area under the curve of glucose (AUC glucose ) was calculated using the trapezoid method from the IPGTT glucose values measured at 0-120 min. Serum high-sensitivity C-reactive protein (hsCRP) and adiponectin levels were measured using rat-specific enzyme-linked immunosorbent assay kits (BD Biosciences Pharmingen, Heidelberg, Germany and AdipoGen Co., Seoul, Republic of Korea, respectively). Tumour necrosis factor (TNF)-a, interleukin (IL)-6, plasminogen activator inhibitor-1 (PAI-1) activity, and monocyte chemoattractant protein-1 (MCP-1) levels were measured using the RADPK-81K kit (Linco, Billerica, MA, USA).
Cell studies
Rat aortic smooth muscle cells (RAoSMCs) were purchased from BioBud (Seoul, Republic of Korea) and cultured in Dulbecco's modified Eagle's medium (DMEM) (Gibco BRL, Grand Island, NY, USA) supplemented with 100 U/mL penicillin-streptomycin, and 10% foetal bovine serum (FBS). Human umbilical vein endothelial cells (HUVECs; Cambrex, Walkersville, MD, USA) were cultured in endothelial cell growth medium (EGM-2) (Cambrex) containing 2% FBS, 0.4% hydrocortisone, 0.1% VEGF, 4% hFGF-B, 0.1% R3-IGF, 0.1% hEGF, 0.1% ascorbic acid, 0.1% GA-1000, and 0.1% heparin, according to the manufacturer's instructions. The RAoSMCs and HUVECs were obtained from the same batches, respectively and cells at 3-6 passages were used. RAoSMCs were starved for 48 h before use, and HUVECs were starved in endothelial cell basal medium (EBM-2; Cambrex) supplemented with 0.2% FBS for 24 h. We repeated all cell studies five times.
Expression of the GLP-1 receptor in RAoSMCs after exenatide or rAd-GLP-1 treatments
To investigate the expression level of the GLP-1 receptor, starved RAoSMCs were treated with various doses (0, 5, 10, 20, or 40 nM) or durations (0, 3, 6, 12, 24, or 48 h) of exenatide. The cells were harvested and were solubilized in cell lysis buffer (Cell Signalling). Protein lysates were subjected to western blotting using an anti-GLP-1 receptor antibody (Santa Cruz Biotechnology).
2.4.1.1 Cell proliferation. Cell proliferation was determined using a modified 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay; 5 mg/mL of MTT was dissolved in phosphate-buffered saline (PBS). RAoSMCs were grown in 48-well plates at a density of 2 Â 10 3 per well starved for 48 h as above, and then placed in DMEM supplemented with 0.5% FBS. The cells were exposed to exenatide (10 nM), rAd-GLP-1 at 5 and 10 multiplicities of infection (MOI), and rAd-bGAL at 10 MOI for 24 h. For platelet-derived growth factor-subunit B (PDGF-BB) stimulation, cells were incubated with 10 ng/mL of PDGF-BB (R&D Systems, Camarillo, USA) for an additional 24 h. Then, a 200 lL aliquot from each well was transferred to a 96-well plate, and light absorbance was measured at 570 nm using a spectrophotometer.
Expression of p27 in RAoSMCs
To measure the expression level of p27, a cell cycle inhibitor protein, starved RAoSMCs were treated with exenatide, rAd-GLP-1, or
Effect of GLP-1 delivery on restenosis rAd-bGAL for 24 h prior to the addition of 10 ng/mL PDGF. The cells were harvested for 24 h after PDGF treatment and were solubilized in cell lysis buffer (Cell Signalling). Protein lysates were subjected to western blotting using an anti-p27 antibody (Cell Signalling).
Analysis of cellular apoptosis by flow cytometry
Starved RAoSMCs were treated with exenatide (10 nM), with rAd-GLP-1 at 5 and 10 MOI, and rAd-bGAL at 10 MOI for 24 h. The cells were harvested, washed with PBS, and fixed in cold 70% ethanol for at least 1 h, and then the cells were stained with 50 lg/mL propidium iodide for 15 min at 37 C. A total of 1 Â 10 4 cells were analysed using a FACScan flow cytometer (Becton Dickson, Franklin Lakes, NJ, USA). The percentages of cells in the apoptotic sub-G1 phase were calculated from the FACScan data.
Cell migration assessed by a wound-healing assay
RAoSMCs were grown to confluence in six-well plates and then starved in DMEM with 0.5% FBS for 48 h. Each well was divided into a 2 3 3 grid. Using a 1000 lL pipette tip, a linear wound was made in each hemisphere of the well. Immediately after wounding, the cells were incubated with 10 ng/mL of PDGF-BB (R&D systems) and were allowed to migrate for 24 h at 37 C. Images were taken around the linear wound. The distance from the line of wounding to the point of maximum cell growth was measured from three fields per well.
Monocyte adhesion assay
To investigate effect of rAD-GLP-1 delivery and exenatide treatment on monocyte adhesion, primary rat monocytes were freshly isolated as previously described with slight modifications. 16 In brief, bone marrow cells from rats were separated using Ficoll and Percoll double gradient centrifugation (GE Healthcare, Buckinghamshire, UK). Fluorescence-labelled rat monocytes were washed three times with serum-free RPMI medium and then resuspended in the same medium. The cells (2 Â 10 4 ) were added to the HUVEC monolayers, stimulated with TNF-a (10 ng/mL) for 18 h, and incubated for 30 min at 37 C in 5% CO 2 in humidified air.
Unbound cells were removed by washing three times with PBS. After being cultured in EBM-2 medium for 24 h, the rat monocytes adhering to endothelial cells were counted in three randomly selected fields of view in each well using microscopy
Western blotting analysis of NF-jB-p65 translocation
Because activation of the NF-jB signalling pathway induces the expression of adhesion molecules in endothelial cells, we investigated the effect of exenatide or rAd-GLP-1 treatment on the nuclear translocation of NF-jB. For this, the HUVECs were pretreated with 10 nM exenatide or infected with rAd-GLP-1 at 10 MOI for 24 h and then stimulated with 20 ng/mL of TNF-a for 15-30 min. Both nuclear and cytosolic fractions were subjected to western blotting using anti-p65 (Santa Cruz Biotechnology) and anti-phospho-IjB (Cell Signalling) antibodies.
MMP2 expression in RAoSMCs and HUVECs
The cells were pretreated with 10 nM exenatide or infected with rAd-GLP-1 at 5 or 10 MOI, and then stimulated with 10 ng/mL of TNF-a for 24 h. Total RNA was isolated from cells using TRIzol reagent (Invitrogen Life Technologies), and RT-PCR was performed according to the manufacturer's instructions. Based on GenBank searching (http://www.ncbi. nlm.nih.gov/genbank/), the RT-PCR primers were designed as follows: MMP-2 sense, 5'-ACCTGTCACTCCGGAGATCTGCAA-3' and
The amplified products were visualized using 1.5% agarose gel electrophoresis and stained with ethidium bromide, and images were then captured under ultraviolet light. Densitometric analysis of the different observations was performed using Quantity One Software (Bio-Rad). The quantity of each transcript was normalized against GAPDH. The effect of exenatide or rAd-GLP-1 treatment on MMP2 expression was also examined in HUVECs. Harvested cells were solubilized in cell lysis buffer (Cell Signalling). Protein lysate concentrations were measured using a Bradford protein assay kit (BioRad). A primary antibody for MMP2 (Santa Cruz) was applied.
MCP-1 and vascular cell adhesion molecule (VCAM) expression measured by RT-PCR
U937 cells and RAoSMCs were pretreated with 10 nM exenatide or infected with rAd-GLP-1 at 10 MOI and then stimulated with 10 ng/mL of TNF-a for 24 h. Total RNA was isolated, and RT-PCR was performed using gene-specific primers for MCP-1: sense, 5'-CTCGCTCAGCCA GATGCAATCAAT-3' and antisense, 5'-CCCAGGGGTAGAACTGT GGTTCAA-3' and VCAM, sense, 5'-ACACCTCCCCCAAGAATAC AG-3', and antisense, 5'-GCTCATCCTCAACACCCACAG-3'. PCR products were analysed using agarose gel electrophoresis and visualized using ethidium bromide.
Statistical analysis
Results are reported as the mean ± standard deviation (SD). The Kolmogorov-Smirnov Goodness of Fit test was used to confirm the normal distribution of key variables. Skewed data distributions such as those for HOMA-IR, HOMA-b, and hsCRP were normalized by logarithmic transformation before all analyses. Mean values were compared for each treatment group by analysis of variance with least significant difference t tests. Analysis was done using IBS SPSS statistics for Windows (version 18.0; IBM Corp., Armonk, NY, USA). For all tests, P < 0.05 was considered to be statistically significant.
Results
Animal studies
GLP-1 receptor expression in carotid arteries
Expression of the GLP-1 receptor was confirmed by western blotting of the harvested vessel tissues (see Supplementary material online, Figure  S1 ). The expression of GLP-1 receptor was increased in the vessel of the exenatide-treated or rAd-GLP-1-delivered rats compared with the control rats, as in a previous study. 17 Both expression levels increased further in the vessels of the rAd-GLP-1-treated rats.
In vivo inhibition of neointimal formation. To determine
whether exenatide treatment or rAd-GLP-1 delivery could alter neointimal formation, we measured the IMR in hematoxylin and eosin (H&E)-stained tissue sections of injured arteries. Two weeks after injury, the exenatide þ rAd-bGAL and NS þ rAd-GLP-1 groups showed a significant reduction in neointimal formation vs. the control group (NS þ rAdbGAL) (Figure 1) . The rAd-GLP-1-delivered rats showed a greater reduction in neointimal formation than the exenatide-treated rats (P < 0.05). Figure 2 , cell proliferation was markedly lower in the exenatide-treated or rAd-GLP-1-delivered groups than in the controls (open arrow). The rAd-GLP-1 group showed a greater reduction in cell proliferation compared with the exenatide-treated rats (P < 0.01).
Inhibited Proliferation of RAoSMCs after Exenatide
As shown in
Sustained apoptosis of vascular cells after exenatide injection or rAd-GLP-1 delivery
Apoptosis of vascular cells was evaluated using TUNEL staining of injured vessels among three groups. After 3 weeks treatment of exenatide or at 2 weeks after balloon injury, the apoptosis index was increased significantly in the exenatide-treated and rAd-GLP-1-delivered groups compared with the control group and further increased in rAd-GLP-1-delivered group compared with the exenatide-treated group (P < 0.01) (Figure 3) .
Expression of CD68 and CD31 after exenatide treatment or rAd-GLP-1 delivery. Infiltrations of monocytes stained with CD68
in the neointimal region were decreased in the rAd-GLP-1-delivered and exenatide-treated rats compared with the rAd-bGAL-delivered rats (Figure 4) . In the injured arteries, endothelial cells stained with CD31 appeared in the injured vessels of the GLP-1-overexpressing and exenatide-treated rats whereas such cells were not observed in the rAdbGAL-delivered rats ( Figure 5 ).
Decreased MMP2 expression after exenatide treatment or rAd-GLP-1 delivery
To clarify whether proliferating smooth muscle cells correspond to the cells expressing MMP2, double staining with an anti-alpha smooth muscle antigen (aSMA) antibody (green) and anti-MMP2 antibody (red) was performed in harvested arteries ( Figure 6 ). Cell nuclei were stained with DAPI (blue). The number of cells expressing MMP2 was significantly lower in the control rats than in the exenatide-treated rats (P < 0.05). A further decrease was found in the rAd-GLP-1-delivered rats (P < 0.05 vs. controls).
Biochemical data associated with cardiovascular risk
Three weeks of treatment of exenatide reduced post-prandial glucose levels at 30 and 60 min significantly, although there was no statistical significance in the reduction of the fasting glucose level ( Table 1) . Glucose tolerance as indicated by the AUC glucose measured in the IPGTT was significantly lower in the exenatide group than in the control or rAd-GLP-1 groups. The HOMA-IR also decreased significantly in the exenatide Treatment with exenatide increased the circulating concentration of adiponectin, which is known to be closely associated with insulin sensitivity. Plasma levels of hsCRP and MCP-1, well known inflammatory markers, were decreased by the exenatide treatment but not in control or rAd-GLP-1 groups ( Table 1 ).
Cell studies
Expression of the GLP-1 receptor in RAoSMCs
In RAoSMCs, exenatide treatment or rAd-GLP-1 delivery increased the expression level of the GLP-1 receptor in time-and dose-dependent manners (see Supplementary material online, Figure S2 ).
RAoSMCs migration and monocyte adhesion in vitro after exenatide or rAd-GLP-1 treatments
Exenatide and rAD-GLP-1 treatments also inhibited the PDGF-BBdirected migration of RAoSMCs ( Figure 7A, B) . TNF-a treatment significantly increased monocyte adhesion in primary rat monocytes, and this was blocked by the treatments with exenatide and delivery of rAd-GLP-1 ( Figure 7C, D) . However, rAd-bGAL delivery did not decrease monocyte adhesion.
Proliferation of RAoSMCs in vitro after exenatide or rAd-GLP-1 treatments
In MTT assays, treatments with exenatide (10 nM) and rAd-GLP-1 (5 and 10 MOIs) inhibited the proliferation in RAoSMCs stimulated with PDGF-BB (see Supplementary material online, Figure S3 ). The proliferation decreased dose-dependently according to the amount of rAd-GLP-1 added.
Expression of p27 and apoptosis in RAoSMCs after exenatide or rAd-GLP-1 treatments
Expression of p27, a cell cycle inhibitor protein, was examined in RAoSMCs. The expression of p27 was decreased by PDGF treatment, but was increased by the treatment with exenatide or rAd-GLP-1, but not by rAd-bGAL (see Supplementary material online, Figure S4 ). Thus, treatment with exenatide and delivery of rAd-GLP-1 delivery inhibited smooth muscle cell proliferation by modulating the cell cycle. When RAoSMCs were incubated with exenatide, the percentage of cells in the sub-G1 phase, indicative of an apoptotic population, was modestly but not significantly increased. In contrast, the sub-G1 population was greatly enriched in GLP-1 overexpressed RAoSMCs (see Supplementary mater ial online, Figure S5 ). 
Effect of exenatide treatment or rAd-GLP-1 delivery on MMP2 expression in RAoSMCs and HUVECs
Exenatide treatment and rAd-GLP-1 delivery reduced MMP2 expression significantly in RAoSMCs (*P < 0.05 vs. rAd-bGAL, **P < 0.05 vs. exenatide in Figure 6C, D) . Expression of activated MMP2 in TNF-a treated HUVECs was also decreased significantly with exenatide treatment or delivery of rAd-GLP-1 compared with rAd-bGAL infection (P < 0.01) (see Supplementary material online, Figure S6 ).
NF-jB-p65 translocation by exenatide treatment or rAd-GLP-1 infection
Treatment with TNF-a (10 ng/ml) induced translocation of NF-jB-p65 into the nucleus, and this was reduced by exenatide treatment (10 nM) and rAd-GLP-1 delivery (5 and 10 MOIs) (*P < 0.05 vs. control, **P < 0.05 vs. exenatide in Figure 8A , B).
Changes in MCP-1 and VCAM expression levels after GLP-1 treatment
The delivery of rAd-bGAL did not affect increased MCP-1 expression in U937 monocytes or VCAM expression in RAoSMCs induced by TNF-a treatment. The rAd-GLP-1 delivery reduced MCP-1 expression significantly, but the effect of exenatide was modest (*P < 0.05 vs. rAd-bGAL, **P < 0.05 vs. exenatide in Figure 8C, D) . Both exenatide treatment and rAd-GLP-1 delivery reduced VCAM expression significantly in RAoSMCs (*P < 0.05 vs. rAd-bGAL, in Figure 8E, F) .
Discussion
This study demonstrated that treatment with a systemic injection of exenatide, a GLP-1 agonist, and direct delivery of rAd-GLP-1 to the carotid artery reduced restenosis after balloon injury in this OLETF rat model of obese T2D. In vivo and in vitro studies showed that rAd-GLP-1 delivery suppressed vascular smooth muscle cell (VSMC) proliferation, promoted VSMC apoptosis, and reduced inflammatory processes more effectively compared with exenatide treatment. Thus, increased GLP-1 activity by direct GLP-1 transduction might have more prominent protective effects against the development of restenosis and possibly atherosclerosis than would systemic GLP-1 agonist administration. This suggests that the local activation of GLP-1 plays an important role in the prevention of restenosis and might be crucial in the prevention of vascular complications in patients with T2D. Previously, it was reported that various cell types including endothelial cells, VSMCs, and cardiomyocytes express a functional GLP-1 receptor. 18 In the present study, the beneficial effect of GLP-1 delivery might have arisen via the GLP-1 receptor because GLP-1 receptor expression was increased by rAd-GLP-1 delivery.
Here, we have demonstrated for the first time direct effects of GLP-1 on the development of restenosis following balloon injury and elucidated its mechanisms using a recombinant adenovirus system. Several studies have already reported the cardioprotective effect of GLP-1 analogues in animal models with heart failure or after acute myocardial infarction. [2] [3] [4] These results have been extended to humans; in patients with T2D and coronary artery disease, GLP-1 infusion significantly increased brachial artery diameters modified by flow mediated dilatation by two-fold from baseline. 19 It has also been reported that pre-treatment with the GLP-1 amide (7-36 amino acids) can protect against ischemic left ventricular dysfunction in patients undergoing elective percutaneous coronary intervention. 20 Recently, liraglutide treatment lowered the rate of the first occurrence of death from cardiovascular causes, non-fatal myocardial infarction, or non-fatal stroke among patients with T2D in a large clinical trial. 6 However, there have been no animal or human studies using direct delivery of GLP-1 into culprit vessels.
Several mechanistic experiments were conducted in our study. MMP2 levels were reduced in the target vessels by GLP-1 transduction. MMP2 is well known to play a fundamental role in the migration of VSMCs in general and matrix remodelling during wound healing, and it is produced by VSMCs, endothelial cells, macrophages, lymphocytes, and mast cells in response to mechanical injury. 21 Activated MMPs are able to degrade extracellular molecules including collagen and elastin, resulting in atherosclerotic effects within the arterial wall. 22 Patients with T2D at high risk for acute coronary events have increased levels of MMP2 and an increased propensity of their atherosclerotic plaques to ulceration and thrombosis. 23, 24 In fact, significant elevations in MMPs 24 h postpercutaneous coronary intervention was associated with the development of instant restenosis following drug-eluting stent implantation. 25 Thus, reduced MMP2 expression caused by GLP-1 delivery appears to be a key mechanism in preventing vascular restenosis. In this study, overexpression of GLP-1 in the injured vessels reduced monocyte infiltration and improved reendothelialization, with stronger effects following direct GLP-1 transfection than with systemic exenatide treatment. Such effects also appear to have contributed to a decrease in neointimal formation. 12, 26 It is well known that infiltration and adhesion of inflammatory cells occurs early after endothelial denudation. [27] [28] [29] Thus, inflammatory and endothelial cells participate in rupture of atherosclerotic plaques. 30 Inhibition of these processes is important in preventing restenosis and mitigating atherosclerosis. 29 In addition, inflammatory and endothelial cells synthesize and secrete MMP2 locally in atherosclerotic lesions. 31 A study on mice fed a high-fat diet showed that treatment with liraglutide (a human GLP-1 analogue; 30 lg/kg twice daily) decreased TNF-a expression and its downstream signalling mediator NF-jB-p65 translocation, and this agent also reduced adhesion of human monocytes to TNF-a-activated human endothelial cells. 32 In our study, the rAd-GLP-1 delivery decreased MMP2 expression in vivo and decreased VSMC migration, MMP2 activation, and monocyte adhesion in vitro. These results imply that direct transduction of GLP-1 might be more effective in the prevention of restenosis than would the systemic GLP-1 analogue treatment.
In the present study, cardiometabolic benefits were observed along with reduction of neointimal formation after exenatide injection for 3 weeks. Previous studies showed that systemic treatment of GLP-1 agonists produced antirestenotic effects. 33, 34 These cardioprotective actions of exenatide seem to be beyond the effects of glucose control and weight loss. 35 Circulating levels of adiponectin, hsCRP, and MCP-1 were altered after the exenatide treatment. MCP-1 has been reported to play an important role in the pathogenesis of atherosclerosis, and evidence suggests that monocytes containing MCPs and macrophages influence the growth of other cell types within atherosclerotic lesions. 36 In the current study, as shown by in vitro and in vivo experiments, the antirestenotic effect of direct rAd-GLP-1 delivery was greater than that of systemic GLP-1 treatment, indicating that it was independent of the systemic effect of GLP-1 analogue treatment.
In a different context, the direct glucose-lowering effects of exenatide and its weight-reducing tendency might contribute to improvements in glucose tolerance in the exenatide-treated rats although the treatment was only for 3 weeks. Systemic reductions in inflammation and increases in adiponectin concentrations by exenatide treatment are also likely to contribute to this improvement. However, systemic GLP-1 agonist treatments have side effects such as gastrointestinal discomforts. Concern about thyroid cancer has not been clearly resolved. Instead, local treatment has advantages such as fewer systemic side effects and optimizing the effect of GLP-1 to a greater extent than systemic treatment.
In conclusion, the local delivery of rAd-GLP-1 to the culprit vessel had protective properties against the development of restenosis in an animal model of insulin resistance. Decreased MMP2 expression and NF-jBp65 translocation, as well as a reduction in the proliferation and migration of RAoSMCs were observed.
Our observations provide, for the first time, a potential mechanism for the vascular benefits of a direct increase in GLP-1 activity, suggesting therapeutic implications for treating macrovascular complications in diabetes. These effects were apparently independent of the glucoselowering effect of incretin-based treatment. Although the feasibility and possible side effects of using a viral vector for increasing GLP-1 levels and preventing atherosclerotic plaque formation warrant further investigations, local activation of GLP-1 might have vasculoprotective effects in a milieu of insulin resistance and atherosclerosis.
